Other News

Five-Year Results of the LEOPARD Trial published in the Journal of Vascular Surgery (JVS)

The LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data) trial is the first randomized controlled trial (RCT) comparing the outcomes of endovascular aneurysm repair (EVAR) using commercially available devices in a real-world population. IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company dedicated to providing disruptive therapies for the interventional treatment […]

10-Year Data from the Medtronic ENGAGE OUS Registry is the First and Only Prospective, Industry Sponsored Global EVAR Registry to Demonstrate a Decade of Durable Outcomes in Real-World Setting

Presented at Charing Cross, 10-Year Clinical Data from Global ENGAGE OUS Registry Support Endurant Stent Graft System’s AAA Market-Leading Position Worldwide Medtronic today announced its EndurantTM abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability through proven outcomes in a real-world setting1. The 10-year Endurant Stent Graft Natural Selection […]

Avinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing System

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for […]

CardieX Receives FDA 510(K) Clearance for a World-First Vascular Biometric Monitor – the CONNEQT Pulse

The world’s first, customizable vascular biometric monitor has received regulatory clearance to provide medical grade arterial heart health metrics to patients and clinicians IRVINE, Calif., April 26, 2023 /PRNewswire/ — CardieX Limited (ASX: CDX) (CardieX, the Company), today announced its new arterial health monitor, the CONNEQT Pulse (Pulse), has received 510(k) clearance from the […]

Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection

OXFORD, England, April 26, 2023 /PRNewswire/ — Ultromics, a leader in the field of artificial intelligence-powered diagnostics for heart failure, has been granted FDA Breakthrough Device Status for its AI-enhanced platform for detecting cardiac amyloidosis. The platform, EchoGo Amyloidosis, uses artificial intelligence to analyse echocardiograms and detect the presence of cardiac amyloidosis, a […]

Capital Health Now Offers Minimally Invasive Aortic Valve Replacement

HOPEWELL, N.J., April 26, 2023 /PRNewswire/ — As part of the growing full-service cardiac program available at Capital Health’s Heart and Vascular Institute, physicians and staff from the Institute’s Structural Heart Program recently performed their first transcatheter aortic valve replacement (TAVR) procedure at Capital Health Regional Medical Center in Trenton, New Jersey. TAVR […]

Boston Scientific Announces Results for First Quarter 2023

MARLBOROUGH, Mass., April 26, 2023 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]

LianBio Announces Positive Topline Results from Phase 3 EXPLORER-CN Trial Evaluating Mavacamten in Chinese Patients

• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a […]

Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Second Quarter Fiscal […]

Vektor Medical Welcomes Two New Advisors to Advance Technology and Commercial Development

SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr. Craig McPherson have joined Vektor’s advisory board. With […]